Education
About Us
Working with TipRanks
Follow Us
Chimeric Therapeutics Ltd. (AU:CHM)
ASX:CHM
Total Valuation
Chimeric Therapeutics Ltd. has a market cap or net worth of AU$11.34M. The enterprise value is AU$14.47M.
Market CapAU$11.34M
Enterprise ValueAU$14.47M
Share Statistics
Chimeric Therapeutics Ltd. has 2,268,209,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,268,209,700
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Chimeric Therapeutics Ltd.’s return on equity (ROE) is -5.07 and return on invested capital (ROIC) is -183.03%.
Return on Equity (ROE)-5.07
Return on Assets (ROA)-0.82
Return on Invested Capital (ROIC)-183.03%
Return on Capital Employed (ROCE)-2.38
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.49
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Chimeric Therapeutics Ltd. is -1.00. Chimeric Therapeutics Ltd.’s PEG ratio is 0.01.
PE Ratio-1.00
PS Ratio21654.24
PB Ratio5.07
Price to Fair Value5.07
Price to FCF1.24K
Price to Operating Cash Flow-1.66
PEG Ratio0.01
Income Statement
In the last 12 months, Chimeric Therapeutics Ltd. had revenue of 7.46M and earned -12.53M in profits. Earnings per share was -0.02.
Revenue7.46M
Gross Profit7.45M
Operating Income-12.31M
Pretax Income-16.28M
Net Income-12.53M
EBITDA-11.30M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -5.51M and capital expenditures 5.78M, giving a free cash flow of 274.83K billion.
Operating Cash Flow-5.51M
Free Cash Flow274.83K
Free Cash Flow per Share<0.01
Dividends & Yields
Chimeric Therapeutics Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.73
52-Week Price Change-66.67%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)2.05M
Important Dates
Chimeric Therapeutics Ltd. upcoming earnings date is Aug 28, 2025, TBA Not Confirmed.
Last Earnings DateFeb 28, 2025
Next Earnings DateAug 28, 2025
Ex-Dividend Date―
Financial Position
Chimeric Therapeutics Ltd. as a current ratio of 0.32, with Debt / Equity ratio of 0.00%
Current Ratio0.32
Quick Ratio0.32
Debt to Market Cap0.00
Net Debt to EBITDA0.27
Interest Coverage Ratio-37.10
Taxes
In the past 12 months, Chimeric Therapeutics Ltd. has paid -3.75M in taxes.
Income Tax-3.75M
Effective Tax Rate0.23
Enterprise Valuation
Chimeric Therapeutics Ltd. EV to EBITDA ratio is -0.84, with an EV/FCF ratio of 936.34.
EV to Sales1.27
EV to EBITDA-0.84
EV to Free Cash Flow936.34
EV to Operating Cash Flow-1.26
Balance Sheet
Chimeric Therapeutics Ltd. has AU$5.07M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of -AU$5.07M billion.
Cash & Marketable SecuritiesAU$5.07M
Total DebtAU$0.00
Net Cash-AU$5.07M
Net Cash Per Share>-AU$0.01
Tangible Book Value Per Share-AU$0.01
Margins
Gross margin is 87.32%, with operating margin of -165.06%, and net profit margin of -168.01%.
Gross Margin87.32%
Operating Margin-165.06%
Pretax Margin-218.30%
Net Profit Margin-168.01%
EBITDA Margin-151.52%
EBIT Margin-165.01%
Analyst Forecast
The average price target for Chimeric Therapeutics Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast28.57%